1. Home
  2. AGIO vs VYX Comparison

AGIO vs VYX Comparison

Compare AGIO & VYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$28.65

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo NCR Voyix Corporation

VYX

NCR Voyix Corporation

HOLD

Current Price

$10.45

Market Cap

1.6B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
VYX
Founded
2007
1881
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
AGIO
VYX
Price
$28.65
$10.45
Analyst Decision
Buy
Buy
Analyst Count
8
6
Target Price
$36.25
$15.25
AVG Volume (30 Days)
1.3M
1.7M
Earning Date
02-12-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$44,791,000.00
$2,653,000,000.00
Revenue This Year
$27.83
N/A
Revenue Next Year
$134.79
N/A
P/E Ratio
N/A
N/A
Revenue Growth
36.26
N/A
52 Week Low
$22.24
$7.55
52 Week High
$46.00
$14.67

Technical Indicators

Market Signals
Indicator
AGIO
VYX
Relative Strength Index (RSI) 52.75 50.16
Support Level $26.25 $9.91
Resistance Level $28.87 $10.84
Average True Range (ATR) 1.09 0.48
MACD 0.25 -0.03
Stochastic Oscillator 74.29 46.03

Price Performance

Historical Comparison
AGIO
VYX

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About VYX NCR Voyix Corporation

NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.

Share on Social Networks: